Pfizer starts to put its vaccine cash to use
After years of U-turns Arena's pivot to bowel disease pays off, with a $6.7bn takeout bid.
Bridgebio sets its heart on besting Pfizer
With phase 3 data approaching, it should soon become clear whether Bridgebio’s amyloidosis project really has an edge over Pfizer’s Vyndaqel.
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Novo’s $3.3bn GalXC quest
The usually conservative group spends big on Dicerna – but others might be interested too.
AHA 2021 – Phasebio takes a step towards reversal agent filing
But questions remain around bentracimab’s data package.
TCT 2021 – Medtronic and Edwards target hard-to-reach valves
Transcatheter technologies could be the future – but a distant one.
